News & Events about Adverum Biotechnologies Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM Get Rating) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,140,000 shares, a decline of 11.9% from the November 30th total of 2,430,000 shares. ...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM Get Rating) was the recipient of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 2,140,000 shares, a decrease of 11.9% from the November 30th total of 2,430,000 shares. Approximately 2.4% of the ...
Globe Newswire
2 months ago
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% 98% reduction in mean annualized anti-VEGF injections ...
Adverum Biotechnologies, Inc. (NASDAQ:ADVM Get Rating) CEO Laurent Fischer sold 41,082 shares of the stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $1.07, for a total value of $43,957.74. Following the completion of the sale, the ...
Globe Newswire
4 months ago
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene ...